InvestorsHub Logo
Followers 87
Posts 5571
Boards Moderated 2
Alias Born 07/06/2014

Re: None

Monday, 06/17/2024 11:02:22 AM

Monday, June 17, 2024 11:02:22 AM

Post# of 26598
well I am in selling mode at this point, I will sell out my entire position if it keeps creeping up to .002. I have no faith in the company or the CEO, enough is enough.

Look its all forward looking statements, as far as I can tell they have done nothing.

If its so good then why arent they moving forward already.

GlobeStar is endeavoring to arrange financing to commence a study of the pharmacokinetic action of the three drugs, and then to initiate a clinical trial. Pharmacokinetics looks at changes in a drug after administration. A pharmacokinetic study generally requires from two weeks to eight weeks.

GlobeStar is discussing the parameters for a pharmacokinetic study with several Clinical Research Organizations (CRO's) in Europe and India. The CRO selected by GlobeStar would assist the company, SMI HealthCare LLC (SMIHC) and Advanced Innovative Partners (AIP) to develop a clinical trial plan. GlobeStar intends to seek FDA guidance in the development of that plan.

Following completion of the pharmacokinetic study, GlobeStar intends to arrange financing for SMIHC to manage an initial clinical trial in India, as well as regulatory filings, intellectual property rights filings, manufacturing, sales and distribution in India, Southeast Asia, Africa, and the Middle East. The clinical trial likely would require approximately three to six months.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GSTC News